BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10954203)

  • 1. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
    Peschen M; Rogers AA; Chen WY; Vanscheidt W
    Acta Derm Venereol; 2000 May; 80(3):162-6. PubMed ID: 10954203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor.
    Kolbach DN; Hamulyák K; Prins MH; Neumann HA; Cleutjens JP
    Vasa; 2004 Feb; 33(1):19-24. PubMed ID: 15061043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
    Rogers AA; Burnett S; Lindholm C; Bjellerup M; Christensen OB; Zederfeldt B; Peschen M; Chen WY
    Vasa; 1999 May; 28(2):101-5. PubMed ID: 10409920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
    Stacey MC; Burnand KG; Mahmoud-Alexandroni M; Gaffney PJ; Bhogal BS
    Br J Surg; 1993 May; 80(5):596-9. PubMed ID: 8518896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
    Herouy Y; Aizpurua J; Stetter C; Dichmann S; Idzko M; Hofmann C; Gitsch G; Vanscheidt W; Schöpf E; Norgauer J
    J Cutan Pathol; 2001 Jul; 28(6):291-7. PubMed ID: 11401675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activation in venous leg ulcers.
    Herouy Y; Trefzer D; Hellstern MO; Stark GB; Vanscheidt W; Schöpf E; Norgauer J
    Br J Dermatol; 2000 Nov; 143(5):930-6. PubMed ID: 11069499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency.
    Peschen M; Lahaye T; Hennig B; Weyl A; Simon JC; Vanscheidt W
    Acta Derm Venereol; 1999 Jan; 79(1):27-32. PubMed ID: 10086854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activators, venous leg ulcers and reepithelialization.
    Lotti T; Benci M
    Int J Dermatol; 1995 Oct; 34(10):696-9. PubMed ID: 8537156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of corneal epithelial defects: role of plasminogen activator.
    Hayashi K; Berman M; Smith D; el-Ghatit A; Pease S; Kenyon KR
    Curr Eye Res; 1991 May; 10(5):381-98. PubMed ID: 1909616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of plasminogen activator enzymes in psoriatic epidermis.
    Spiers EM; Lazarus GS; Lyons-Giordano B
    J Invest Dermatol; 1994 Mar; 102(3):333-8. PubMed ID: 8120416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous findings in patients with chronic venous insufficiency.
    Kılınç F; Akbaş A; Şener S; Hayran Y; Aktaş A
    J Cosmet Dermatol; 2022 May; 21(5):2106-2112. PubMed ID: 34240795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
    Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
    EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
    Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E
    Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency.
    Peschen M; Grenz H; Brand-Saberi B; Bunaes M; Simon JC; Schöpf E; Vanscheidt W
    Arch Dermatol Res; 1998 Jun; 290(6):291-7. PubMed ID: 9705159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
    Lagattolla NR; Stacey MC; Burnand KG; Gaffney PG
    Ann Cardiol Angeiol (Paris); 1995; 44(6):299-303. PubMed ID: 7574362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice.
    Cooper JM; Rastogi A; Krizo JA; Mintz EM; Prosser RA
    Eur J Neurosci; 2017 Mar; 45(6):805-815. PubMed ID: 27992087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development.
    Li M; Karakji EG; Xing R; Fryer JN; Carnegie JA; Rabbani SA; Tsang BK
    Endocrinology; 1997 Jul; 138(7):2790-9. PubMed ID: 9202219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of skin pathologic changes and ulceration].
    Qian HS
    Zhonghua Yi Xue Za Zhi; 1993 Jun; 73(6):352-4, 381-2. PubMed ID: 8258106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.